GNTA
Genenta Science S.p.A.
stockNASDAQADR
cancer immunotherapy - our gene therapy science to treat cancer we develop a gene transfer strategy into autologous hematopoietic stem/progenitor cells (hspcs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. an hiv-derived and genetically disabled viral vector - lentivirus - delivers the gene into the hspcs. interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. however, the clinical use of interferon as a drug has been limited by its high toxicity. thanks to our innovative therapy, using a combination of transcriptional and microrna-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity. based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, tie2-expressing monocytes (tems), are armed with a specific drug.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.62 | 2026-10-26 | +27.79% | -0.613 |
| 1M | 0.75 | 2026-10-02 | +7.10% | 1.769 |
| 3M | 1.41 | 2026-08-03 | -43.41% | 0.391 |
| 6M | 0.73 | 2026-05-01 | +9.30% | 1.392 |
| 1Y | 2.56 | 2025-11-03 | -68.83% | 1.733 |
| 2Y | 5.45 | 2024-11-01 | -85.36% | — |
| 5Y | 11.00 | 2021-12-15 | -92.75% | 0.223 |
Genenta Science S.p.A. (NASDAQ:GNTA) stock price today is $0.80, and today's volume is 991,987. GNTA is up 29.047% today. The 30 day average volume is 57,668. GNTA market cap is $38.47M with 48.22M shares outstanding.